Antiviral efficacy of pralatrexate against sars-cov-2

Joon Yong Bae; Gee Eun Lee; Heedo Park; Juyoung Cho; Jeonghun Kim; Jungmin Lee; Kisoon Kim; Jin Il Kim; Man Seong Park

doi:10.4062/biomolther.2021.032

Antiviral efficacy of pralatrexate against sars-cov-2

Joon Yong Bae, Gee Eun Lee, Heedo Park, Juyoung Cho, Jeonghun Kim, Jungmin Lee, Kisoon Kim, Jin Il Kim, Man Seong Park

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

Original language	English
Pages (from-to)	268-272
Number of pages	5
Journal	Biomolecules and Therapeutics
Volume	29
Issue number	3
DOIs	https://doi.org/10.4062/biomolther.2021.032
Publication status	Published - 2021

Bibliographical note

Publisher Copyright:
© 2021 The Korean Society of Applied Pharmacology.

Keywords

Antiviral
COVID-19
Drug repurposing
SARS-CoV-2

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.4062/biomolther.2021.032

Cite this

@article{194a147daa9e41cc818af0b549e6d41e,

title = "Antiviral efficacy of pralatrexate against sars-cov-2",

abstract = "Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.",

keywords = "Antiviral, COVID-19, Drug repurposing, SARS-CoV-2",

author = "Bae, {Joon Yong} and Lee, {Gee Eun} and Heedo Park and Juyoung Cho and Jeonghun Kim and Jungmin Lee and Kisoon Kim and Kim, {Jin Il} and Park, {Man Seong}",

note = "Publisher Copyright: {\textcopyright} 2021 The Korean Society of Applied Pharmacology.",

year = "2021",

doi = "10.4062/biomolther.2021.032",

language = "English",

volume = "29",

pages = "268--272",

journal = "Biomolecules and Therapeutics",

issn = "1976-9148",

publisher = "Korean Society of Applied Pharmacology",

number = "3",

}

TY - JOUR

T1 - Antiviral efficacy of pralatrexate against sars-cov-2

AU - Bae, Joon Yong

AU - Lee, Gee Eun

AU - Park, Heedo

AU - Cho, Juyoung

AU - Kim, Jeonghun

AU - Lee, Jungmin

AU - Kim, Kisoon

AU - Kim, Jin Il

AU - Park, Man Seong

PY - 2021

Y1 - 2021

N2 - Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

AB - Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community. However, only limited access has been allowed to COVID-19 vaccines and antiviral treatment options. Here, we report the efficacy of the anticancer drug pralatrexate against SARS-CoV-2. In Vero and human lung epithelial Calu-3 cells, pralatrexate reduced viral RNA copies of SARS-CoV-2 without detectable cytotoxicity, and viral replication was successfully inhibited in a dose-dependent manner. In a time-to-addition assay, pralatrexate treatment at almost half a day after infection also exhibited inhibitory effects on the replication of SARS-CoV-2 in Calu-3 cells. Taken together, these results suggest the potential of pralatrexate as a drug repurposing COVID-19 remedy.

KW - Antiviral

KW - COVID-19

KW - Drug repurposing

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85106509753&partnerID=8YFLogxK

U2 - 10.4062/biomolther.2021.032

DO - 10.4062/biomolther.2021.032

M3 - Article

AN - SCOPUS:85106509753

SN - 1976-9148

VL - 29

SP - 268

EP - 272

JO - Biomolecules and Therapeutics

JF - Biomolecules and Therapeutics

IS - 3

ER -

Antiviral efficacy of pralatrexate against sars-cov-2

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this